Geneva, Dec. 23 -- International Clinical Trials Registry received information related to the study (ISRCTN10651912) titled 'First-in-human study of RO7812653' on Dec. 11.

Study Type: Interventional

Study Design: Double-blind randomized placebo-controlled parallel-group trial (Safety)

Primary Sponsor: F. Hoffmann-La Roche AG

Condition: Early symptomatic Alzheimer's disease (eAD) Nervous System Diseases

Intervention: 1. RO7812653: Participants will receive a dose of RO7812653 as per the schedule in the protocol. 2. Placebo: Participants will receive a dose of placebo as per the schedule in the protocol....

Recruitment Status: Recruiting

Phase: Phase I

Date of First Enrollment: 28/11/2025

Target Sample Size: 45

Countries o...